Annexon (ANNX) stock: insider trades, news & valuation
Health Care · Strong buyingShare price and insider trades
Annexon insider trading at a glance (Oct 9, 2026): in the past 12 months, 4 insiders bought $12.4M and 5 sold $313K of ANNX stock on the open market, including a cluster buy that began Nov 17, 2025.
Get emailed when insiders cluster-buy stocks like ANNX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ANNX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | $100K | 1 | — | 0 |
| Q2 2026 | $3.4M | 3 | — | 0 |
| Q1 2026 | $45K | 1 | $313K | 10 |
| Q4 2025 | $8.8M | 9 | — | 0 |
| Q3 2025 | $13K | 1 | — | 0 |
Valuation, profit and volume
Pick score 46/100Summary
Over the past 12 months, 4 Annexon, Inc. insiders reported open-market purchases totaling $12.4M, while 5 insiders reported sales totaling $313K. The most recent cluster buy began on Nov 17, 2025, when 3 insiders bought a combined $8.8M. Among insiders with enough purchase history to measure, William H. Carson (Director) has the highest Insider Score at 95. 0 of 10 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
ANNX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Aug 12, 2026 | +4.1% | None | -1.5%S&P +0.9% | -25.1% |
| May 7, 2026 | -8.1% | Bought $50K | -0.2%S&P +0.5% | -7.0% |
| Mar 30, 2026 | -8.1% | Bought $45K Sold $147K |
+10.8%S&P +2.6% | +6.0% |
| Nov 10, 2025 | -5.6% | Bought $13K | +3.1%S&P +1.8% | +69.7% |
| Aug 14, 2025 | +9.2% | None | -6.2%S&P -0.2% | -0.8% |
| May 12, 2025 | -16.2% | None | +9.4%S&P +4.0% | +54.9% |
| Mar 3, 2025 | -12.3% | None | -6.4%S&P -2.9% | -25.9% |
| Nov 14, 2024 | -13.5% | None | -6.6%S&P -1.9% | -27.5% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
ANNX news sentiment trend
Weekly headline tone (positive minus negative headlines) over 13 weeks. Green dots mark weeks with insider buying.
Tone is scored from headline wording only. It describes the news, not where the stock is going.
ANNX stock news and SEC filings
Recent 8-K filings and headlines. Tone is scored from the headline wording; “Policy” marks regulatory, trade or government topics.
- News Annexon ( NASDAQ : ANNX ) Shares Climb 5 . 1 % – Still a Buy ? · themarketsdaily.com
- News Research Analyst Price Target Changes for September 30th ( ALNY , ANAB , ANNX , AXP , BCRX , BYN , CAS , CE , CTAS , EMN ) · tickerreport.com
- News Annexon ( NASDAQ : ANNX ) Given New $15 . 00 Price Target at JPMorgan Chase & Co . · dailypolitical.com
- News New antibody treatment blocks immune response to prevent Alzheimer damage · news-medical.net
- News Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting · manilatimes.net
- 8-K Earnings release, Other material event
- 8-K Executive or board change, Investor disclosure
- 8-K Other material event
- 8-K Material agreement, New debt obligation, Other material event
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 25SEC | Douglas LoveCEO, President | Buy | 26,065390,476 held (+7%) | $3.83 | $100K | +5.0% | — |
| May 29SEC | Muneer A SatterDirector | Buy | 613,49710,342,134 held (+6%) | $5.41 | $3.3M | -25.7% | 70 |
| May 13SEC | William H. CarsonDirector | Buy | 8,00078,405 held (+11%) | $5.78 | $46K | -30.4% | 95 |
| Apr 14SEC | William H. CarsonDirector | Buy | 8,00070,405 held (+13%) | $6.20 | $50K | -35.2% | 95 |
| Mar 12SEC | William H. CarsonDirector | Buy | 8,00062,405 held (+15%) | $5.67 | $45K | -29.1% | 95 |
| Mar 4SEC | Dean Richard ArtisEvp & Chief Scientific Officer | Sell | 5,894180,093 held (−3%) | $5.43 | $32K | -26.0% | — |
| Mar 4SEC | Jamie DananbergChief Medical Officer | Sell | 5,820123,582 held (−4%) | $5.43 | $32K | -26.0% | — |
| Mar 4SEC | Ted YednockEvp & Chief Innovation Officer | Sell | 5,566154,161 held (−3%) | $5.42 | $30K | -25.8% | — |
| Mar 4SEC | Jennifer LewCFO | Sell | 5,565170,700 held (−3%) | $5.42 | $30K | -25.8% | — |
| Mar 4SEC | Michael OverdorfEvp & Chief Business Officer | Sell | 4,339182,625 held (−2%) | $5.42 | $24K | -25.8% | — |
| Feb 20SEC | Ted YednockEvp & Chief Innovation Officer | Sell | 7,85797,227 held (−7%) | $5.11 | $40K | -21.3% | — |
| Feb 20SEC | Jennifer LewCFO | Sell | 7,851113,765 held (−6%) | $5.11 | $40K | -21.3% | — |
| Feb 20SEC | Michael OverdorfEvp & Chief Business Officer | Sell | 6,225124,464 held (−5%) | $5.10 | $32K | -21.2% | — |
| Feb 20SEC | Jamie DananbergChief Medical Officer | Sell | 5,29073,152 held (−7%) | $5.10 | $27K | -21.2% | — |
| Feb 20SEC | Dean Richard ArtisEvp & Chief Scientific Officer | Sell | 5,290123,487 held (−4%) | $5.10 | $27K | -21.2% | — |
| Jan 2SEC | William H. CarsonDirector | Buy | 4,11554,405 held (+8%) | $5.02 | $21K | -19.9% | 95 |
| Dec 3SEC | Jung ChoiDirector | Buy | 33,000new position | $4.19 | $138K | -4.1% | — |
| Dec 3SEC | William H. CarsonDirector | Buy | 4,11550,290 held (+9%) | $4.47 | $18K | -10.1% | 95 |
| Nov 21SEC | Muneer A SatterDirector | Buy | 422,6139,728,637 held (+5%) | $4.28 | $1.8M | -6.1% | 70 |
| Nov 21SEC | Muneer A SatterDirector | Buy | 400,0009,306,024 held (+4%) | $4.48 | $1.8M | -10.3% | 70 |
| Nov 19SEC | Muneer A SatterDirector | Buy | 500,0008,906,024 held (+6%) | $3.94 | $2.0M | +2.0% | 70 |
| Nov 19SEC | Muneer A SatterDirector | Buy | 500,0008,406,024 held (+6%) | $3.18 | $1.6M | +26.4% | 70 |
| Nov 19SEC | Muneer A SatterDirector | Buy | 500,0007,906,024 held (+7%) | $2.99 | $1.5M | +34.4% | 70 |
| Oct 31SEC | William H. CarsonDirector | Buy | 4,11546,175 held (+10%) | $3.17 | $13K | +26.8% | 95 |
| Oct 2SEC | William H. CarsonDirector | Buy | 4,11542,060 held (+11%) | $3.05 | $13K | +31.8% | 95 |
Insiders at Annexon, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Muneer A SatterDirector | $12.0M | — | May 29, 2026 | 70 |
| William H. CarsonDirector | $206K | — | May 13, 2026 | 95 |
| Jung ChoiDirector | $138K | — | Dec 3, 2025 | — |
| Douglas LoveCEO, President | $100K | — | Sep 25, 2026 | — |
| Ted YednockEvp & Chief Innovation Officer | — | $70K | Mar 4, 2026 | — |
| Jennifer LewCFO | — | $70K | Mar 4, 2026 | — |
| Dean Richard ArtisEvp & Chief Scientific Officer | — | $59K | Mar 4, 2026 | — |
| Jamie DananbergChief Medical Officer | — | $59K | Mar 4, 2026 | — |
| Michael OverdorfEvp & Chief Business Officer | — | $55K | Mar 4, 2026 | — |
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
ANNX stock: common questions
Are Annexon, Inc. insiders buying ANNX stock?
In the past 12 months, 4 insiders reported open-market purchases of ANNX worth $12.4M. The latest was CEO, President Douglas Love bought $100K of ANNX at $3.83 — first open-market purchase in our records.
Are Annexon, Inc. insiders selling ANNX stock?
5 insiders reported sales worth $313K over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ANNX's 52-week range?
Over the past year ANNX has traded between $2.68 and $6.96. It last closed at $4.02 on Oct 9, 2026.